An autologous tumour vaccine modified with recombinant new castle disease virus to express IL-7 promotes anti-tumour immune responses in murine models by increasing the IFN-γ production and cytotoxicity of CD8+ T-cells [63]. The gene discussed is CD8A; the disease is neoplasm.